Major Challenges 1
Shortage of pathologists and the resultant increase in workload
In the US, the number of active pathologists dropped by 18% from 2007 to 2017. In South Korea, only 7 graduates enrolled in pathology residency where 65 slots were available in 2020.
Major Challenges 2
Discordance among pathologists in diagnosis
With varying levels of talent and experience, pathologists notice different things and have different perspectives on what is important which results in inconsistency and discordance among pathologists in diagnoses.
Benefits of using DeepDx
Accuracy in quantifying the areas of interest in ratios
Quality check for any potential missed areas of interest
Consistency and reproducibility of diagnoses
Deep Bio’s deep learning-based cancer diagnostic support software minimizes the risk of human error from manual handling and subjectivity of pathologist assessment resulting in decreased turnaround time, more precise and consistent diagnostic results, and improved reproducibility. Precise classification and quantification of different morphological patterns and cells offer new insights and relationships that can help medical professionals optimize their decisions and determine the best treatment options for patients.
Sun Woo Kim, the founder and CEO of Deep Bio Inc., has a proven track record of over 20 years in executive management as well as computer science expertise. He founded Deep Bio based on the firm belief that AI can revolutionize healthcare and address some of the existing challenges, starting with improved diagnostic processes. Prior to founding Deep Bio, he served as the Chief Technology Officer of Pinion Industries, an automotive software and security start-up, which was acquired by Hyundai Motors in 2014. He was also the deputy director of Korea Telecommunications, the largest telecommunications company in Korea, where he led the global venture capital team.
Tae Yeong Kwak has unmatched expertise across a span of computer programming subspecialties, including algorithm design, computer systems design, and big data analysis. Prior to joining Deep Bio, he was at Netmarble, Korea’s biggest mobile gaming company, where he directed their AI Lab and also managed big data analysis and systems operations. At Naver Corporation, the first company in Korea to launch an online platform, he led the natural language processing machine learning team.
Prior to joining Deep Bio, Byeong Hak Kim had built an illustrious career of directing machine learning departments at global companies such as Kakao, Samsung, Naver, etc., for nearly 30 years. Notably, he has served in leadership positions such as the Head of the Center for Machine Learning at Naver, as well as Vice President of AI at Kakao, where he developed machine learning algorithms and variety of products and services that utilize them. He is the head of product development at Deep Bio, and leads the next generation of medical services.
Hoi Chang Chung is KICPA certified, and as the Chief Financial Officer, has contributed to overseeing all financial accounts and coordinating audit activities of Deep Bio. Before joining Deep Bio, Hoi Chang Chung was the Head of Finance at companies in diverse industries including pharmaceutical, insurance, education and finance. He has extensive experience in managing finance, fund raising, budgeting and IPO preparations.
Yong Hyun Hwang has over 20 years of experiences working for multinational companies such as Google, Microsoft, Qualcomm, and Oracle as a software engineer and a researcher. Yong Hyun Hwang holds extensive knowledge, capability and experiences in innovating, architecting and designing new infrastructures and toolsets to improve existing workflow and developer proficiency. At Google, he led and completed a project that saves Google data center more than $150 million per year.
Dr. Hye Yoon Chang, Deep Bio’s Medical Officer, brings more than twenty years of experience as a board-certified pathologist specializing in anatomic pathology. She holds a medical degree and a Ph.D. from Korea University, the nation’s top institution in medical research, where she also completed her residency. Hye Yoon has authored numerous papers on ground-breaking research in clinical pathology and serves as a member of the Korean Pathology Society and Korean Cytology Society.